関連ニュース

Omega Healthcare Investors is downgraded from buy to hold as growth appears fully priced in near current levels. OHI delivered strong Q2 results, with AFFO guidance raised to $3.22–$3.26 and a 4.2% gr

Omega Healthcare remains Buy rated, offering a near 6% yield and structural advantages in skilled nursing real estate. OHI's upcoming earnings are expected to be quietly strong, with AFFO/share modele

Omega Healthcare Investors NYSE: OHI reported second-quarter 2026 results marked by higher revenue, a large gain from asset sales, improved portfolio coverage and an increased full-year Adjusted FFO o